Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Etripamil NS
DRUG
2 trials
Sponsors
Milestone Pharmaceuticals Inc.
Conditions
Paroxysmal Supraventricular Tachycardia
Phase 2
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
Recruiting
NCT05763953
Milestone Pharmaceuticals Inc.
Paroxysmal Supraventricular Tachycardia
Start: 2023-12-11
End: 2027-06-30
Target: 60
Updated: 2026-07-21
Phase 3
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
Completed
NCT04072835
Milestone Pharmaceuticals Inc.
Paroxysmal Supraventricular Tachycardia
Start: 2019-09-23
End: 2023-01-26
Updated: 2024-05-23
Related Papers
Self‐Administered Etripamil Nasal Spray Slows Ventricular Rate in Patients With Atrial Fibrillation: A Post Hoc Analysis of the NODE‐303 Study
Journal of Cardiovascular Electrophysiology
2026-02-10
Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE‐303 Open‐Label Study
Journal of Cardiovascular Electrophysiology
2025-09-11
2 citations
Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)
Circulation Arrhythmia and Electrophysiology
2023-11-11
10 citations